BioLexis’ Acquisition of $20 Million Oncobiologics’ Common Stock


Shearman & Sterling advised BioLexis Pte. Limited (formerly known as “GMS Tenshi Holdings Pte. Limited”) in connection with its purchase, in a private placement, of up to an additional $20 million of the common stock of Oncobiologics.

This investment is BioLexis’ third investment in Oncobiologics. The private placement is expected to close in four tranches, subject to customary closing conditions and achievement of certain funding milestones, including the amendment of BioLexis’ senior secured notes.

Shearman & Sterling advised BioLexis Pte. Limited with a team including Brien Wassner (Picture), Gus Atiyah, Lona Nallengara, Alan S. Goudiss, Jordan Altman, Joel Moss, Gillian Emmett Moldowan, Nathan Wood, Christopher Tomlinson and Matthew Weston

Involved fees earner: Jordan Altman – Shearman & Sterling; Gus Atiyah – Shearman & Sterling; Gillian Emmett Moldowan – Shearman & Sterling; Alan Goudiss – Shearman & Sterling; Joel Moss – Shearman & Sterling; Lona Nallengara – Shearman & Sterling; Christopher Tomlinson – Shearman & Sterling; Brien Wassner – Shearman & Sterling; Matthew Weston – Shearman & Sterling; Nathan Wood – Shearman & Sterling;

Law Firms: Shearman & Sterling;

Clients: BioLexis Pte. Limited;